The CRIPSR-edited neoantigen-specific T cell therapy demonstrated safety and feasibility in the first-in-human PACT-0101 study presented at SITC 2022.
Susan Foy, PhD
Advertisement
Articles by Susan Foy, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CGTlive®
1
Autologous Stem Cell Therapy for Alzheimer Disease Advances to Phase 2 After Positive Early Findings
2
FasTCAR Manufactured BCMAxCD19 CAR T-cell Therapy Shows Promise for Multiple Myeloma
3
FDA Approves BMS’s Liso-Cel for R/R Marginal Zone Lymphoma
4
CGTLive®’s Weekly Rewind – December 5, 2025
5
